Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
COVID-19
/ complications
Case-Control Studies
Cohort Studies
Female
Hospitalization
/ statistics & numerical data
Humans
Male
Middle Aged
Pneumonia, Viral
/ complications
Prospective Studies
SARS-CoV-2
/ immunology
Treatment Outcome
COVID-19
Canakinumab
Pneumonia
SARS-CoV-2
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
24
09
2020
revised:
23
12
2020
accepted:
23
12
2020
pubmed:
2
1
2021
medline:
24
4
2021
entrez:
1
1
2021
Statut:
ppublish
Résumé
Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study: 33 patients (cases) signed informed consent and received canakinumab (Cohort 1) and 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (Cohort 2). Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs. 26 days, respectively; p < 0.001). There was significant clinical improvement in ventilation regimes following administration of canakinumab compared with Cohort 2 (Stuart-Maxwell test for paired data, p < 0.001). Patients treated with canakinumab experienced a significant increase in PaO Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favourable prognosis versus standard of care.
Identifiants
pubmed: 33385581
pii: S1201-9712(20)32597-2
doi: 10.1016/j.ijid.2020.12.073
pmc: PMC7771302
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
canakinumab
37CQ2C7X93
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
433-440Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
PLoS One. 2020 Jul 9;15(7):e0235458
pubmed: 32645044
J Breast Cancer. 2019 Sep 18;22(3):425-438
pubmed: 31598342
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Rheumatol. 2020 Aug;2(8):e457-ee458
pubmed: 32835251
Microorganisms. 2020 May 09;8(5):
pubmed: 32397399
MAbs. 2014 May-Jun;6(3):765-73
pubmed: 24671001
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Sci Rep. 2019 Feb 4;9(1):1390
pubmed: 30718599
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Med Hypotheses. 2020 Jul;140:109749
pubmed: 32339777
Arch Med Res. 2020 Aug;51(6):473-481
pubmed: 32499154
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Infez Med. 2020 Ahead of print Jun 1;28(2):143-152
pubmed: 32275256
Inflamm Res. 2021 Jan;70(1):7-10
pubmed: 33079210
Arch Virol. 2020 Aug;165(8):1729-1737
pubmed: 32514689
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Med Mal Infect. 2020 Aug;50(5):397-400
pubmed: 32387320